De novo drug design has moved from a niche computational exercise to a central pillar of AI-driven drug discovery. With rising R&D costs, multi-year timelines, and high attrition rates, the ability toRead More…
As operators of Creative Biolabs’ AI Station, we’ve watched artificial intelligence move natural-product (NP) drug discovery from scattered experiments to data-driven pipelines. A recent perspective captures this shift with unusual clarity: AIRead More…
The landscape of cancer treatment is undergoing a radical transformation, driven by the emergence of messenger RNA (mRNA) vaccines. These versatile and scalable platforms are not just a new tool; they representRead More…
The design of therapeutic antibodies has long been a cornerstone of modern biopharmaceutical innovation. Yet traditional discovery pipelines—reliant on animal immunization, patient-derived antibodies, and wet-lab optimization—are inherently slow, costly, and difficult toRead More…
In the evolving landscape of biologics, monoclonal antibodies (mAbs) have emerged as one of the most powerful therapeutic modalities, offering high specificity, prolonged half-life, and unparalleled versatility in disease targeting. Yet, despiteRead More…
Artificial intelligence (AI) is rapidly transforming the landscape of therapeutic antibody discovery and engineering. As the biopharmaceutical industry continues to demand faster, more precise, and cost-effective development pipelines, AI-driven solutions have emergedRead More…
Antibody-based therapeutics have emerged as one of the most successful classes of biologics for cancer treatment. Yet, the development of these complex biomolecules remains a formidable task, requiring the integration of structuralRead More…
Introduction: The New Era of Antibody Engineering The field of antibody engineering has driven biomedical innovation for many years by supplying crucial resources for therapeutic development and research diagnostics. Hybridoma technology andRead More…
The Limitations of Traditional Antibody Discovery and AI’s Disruptive Potential For decades, antibody drug development has relied on labor-intensive methods such as hybridoma technology and phage display—processes that often requiring 10-15 yearsRead More…
Introduction: The Convergence of AI and Medicine In recent years, the intersection of artificial intelligence (AI) and healthcare has emerged as one of the most promising frontiers. Among the myriad applications, theRead More…